Peptide education
Pegvisomant
Somavert
Pegvisomant is a modified growth hormone protein that blocks growth hormone receptors. The US prescription product Somavert is used for acromegaly in patients whose surgery or radiation has not worked adequately or is not appropriate.
During a 12-week randomized study of 112 patients with acromegaly, IGF-1 normalized at least once after baseline in 89% of the group receiving 20 mg daily and 10% of the placebo group. In the FDA's endpoint analysis, IGF-1 was normal in 23 of 28 patients on 20 mg and 3 of 31 on placebo.
Overview
Quick answer
Unlike a growth hormone replacement medicine, pegvisomant blocks growth hormone action. It lowers IGF-1, but biochemical control is not proof of tumor shrinkage.
What is pegvisomant used for?
Somavert is labeled for acromegaly when surgery or radiation has not provided an adequate response or those treatments are not appropriate. The treatment goal is to normalize serum IGF-1.
Is it a form of growth hormone replacement?
No. Pegvisomant is derived from a growth hormone analog but acts as an antagonist at its receptor, reducing growth hormone signaling and IGF-1.
How is Somavert given?
The US label describes a 40 mg subcutaneous loading dose under healthcare provider supervision, followed the next day by 10 mg once daily. The maintenance dose is adjusted to IGF-1 results.
Why are liver tests needed?
Liver enzyme elevations and liver injury have been reported. The label specifies baseline liver tests and a monitoring schedule during treatment.
Evidence
Evidence snapshot
During the 12-week study, IGF-1 normalized at least once after baseline in 54%, 81% and 89% of the 10 mg, 15 mg and 20 mg daily groups, compared with 10% on placebo. These figures are not the week-12 response rates.
The label directs dose adjustment using IGF-1 rather than growth hormone measurements or symptoms alone.
Liver injury has been reported, and people taking diabetes medication may need closer glucose monitoring because hypoglycemia can occur.
Lower IGF-1 describes biochemical control; it does not establish that the underlying pituitary tumor has shrunk.
Claims
Common claims vs evidence
| Claim | Human evidence | Mechanistic evidence | Verdict |
|---|---|---|---|
| Pegvisomant can normalize IGF-1 in acromegaly. | During a 12-week trial, the proportion with normal IGF-1 at least once after baseline increased across the three active dose groups and was higher than with placebo. | Supported in the studied acromegaly population, with individual variation. | |
| Normal IGF-1 proves the pituitary tumor has shrunk. | The controlled trial measured serum IGF-1 and symptoms. A biochemical response does not by itself demonstrate tumor shrinkage or cure. | These are separate outcomes. | |
| Pegvisomant is a substitute for growth hormone replacement. | The cited trial studied treatment of acromegaly, not growth hormone deficiency. | Pegvisomant blocks growth hormone receptor activity and reduces IGF-1 rather than supplying growth hormone activity. | No. Its action and labeled indication are different. |
Bottom line
Main takeaway
Pegvisomant blocks growth hormone action in a condition where too much growth hormone is present.
IGF-1 and liver tests guide treatment; glucose and the underlying pituitary disease also need attention.
The 12-week placebo-controlled study measured biochemical response and symptoms, not long-term tumor control.
Identity
What it is
Pegvisomant is an engineered growth hormone analog attached to polyethylene glycol. Its receptor-blocking action lowers production of IGF-1.
Somavert is supplied as a powder for reconstitution and given by subcutaneous injection. The loading dose is given under healthcare provider supervision.
Use context
Routes, doses, and cycle patterns
Somavert dosing is adjusted using serum IGF-1 and the patient's clinical circumstances.
Human studies and product labels
Somavert loading dose
- Purpose
- Initiation of treatment for acromegaly
- Context
- US prescribing information
- Route
- Subcutaneous injection under healthcare provider supervision
- Amount
- 40 mg
- Frequency
- Once at initiation
The label describes the loading dose as two 20 mg injections at different sites.
Somavert maintenance dose
- Purpose
- Normalize serum IGF-1 in the labeled setting
- Context
- US prescribing information
- Route
- Subcutaneous injection
- Amount
- 10 mg initially
- Frequency
- Once daily starting the day after the loading dose
IGF-1 is measured every 4 to 6 weeks for dose adjustment in 5 mg steps. The labeled maintenance range is 10 to 30 mg daily, with a 30 mg daily maximum.
Placebo-controlled acromegaly trial
- Purpose
- Assess IGF-1 and clinical signs in acromegaly
- Context
- Randomized double-blind study
- Route
- Subcutaneous injection
- Amount
- 10 mg, 15 mg or 20 mg
- Frequency
- Once daily
- Duration
- 12 weeks
Active groups received an 80 mg study loading dose before fixed daily doses. The current US label specifies a 40 mg loading dose.
Research
Research evidence
A 12-week trial found dose-related reductions in IGF-1 compared with placebo. The label describes ongoing IGF-1 and liver testing during treatment.
| Study / evidence area | Population | Design | Product context | Main outcome | Limitations | Weight |
|---|---|---|---|---|---|---|
| Pegvisomant acromegaly trial | 112 patients with acromegaly | Randomized double-blind placebo-controlled study over 12 weeks | Subcutaneous pegvisomant 10, 15 or 20 mg daily after an 80 mg study loading dose, or placebo | IGF-1 normalized at least once after baseline in 54%, 81% and 89% of the active groups versus 10% with placebo. The FDA endpoint analysis found normal IGF-1 in 23 of 28 patients on 20 mg and 3 of 31 on placebo. | The study was short, used a different loading dose than the current US label, and did not establish long-term tumor control. | Randomized, placebo-controlled |
Cautions
Safety and unknowns
- Liver enzyme elevations and liver injury have been reported. Baseline liver tests and subsequent monitoring are specified in the label.
- Patients taking insulin or other diabetes medicines may develop hypoglycemia as glucose tolerance changes and may need treatment adjustment.
- Injection-site lipohypertrophy and systemic hypersensitivity can occur. Injection sites are rotated to reduce local reactions.
- Pegvisomant can interfere with growth hormone assays. Its label directs dose adjustment using IGF-1, not measured growth hormone concentrations.
Mechanism
How it is proposed to work
Pegvisomant blocks growth hormone receptors, reducing growth hormone signaling and lowering IGF-1.
The modified growth hormone analog is attached to polyethylene glycol and acts as a receptor antagonist.
IGF-1 is the label's treatment target; a falling IGF-1 level alone does not establish tumor shrinkage.
Details
Technical details
Sources
References
- 1.
US prescribing information. Somavert prescribing information
US label covering acromegaly, dosing, IGF-1 monitoring and liver safety.
- 2.
PubMed. Treatment of acromegaly with the growth hormone receptor antagonist pegvisomant
doi:10.1056/NEJM200004203421604 PMID:10770982
Randomized placebo-controlled, 12-week study of three daily doses in patients with acromegaly.
- 3.
FDA. FDA review of the pegvisomant acromegaly study
FDA medical review reports the study's loading dose and daily treatment arms.
- 4.
FDA. FDA statistical review of the pegvisomant acromegaly study
Distinguishes IGF-1 normalization at any post-baseline visit from the reviewer's endpoint analysis.